Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Randomized, Double-blind, Two-arm, Placebo-controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of RGH-202 for the Management of Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder

NCT07931703 is registered in ClinicalTrials.gov with Gedeon Richter Plc. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07931703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Randomized, Double-blind, Two-arm, Placebo-controlled Clinical Trial to Assess the Safety, Tolerability and Efficacy of RGH-202 for the Management of Performance and Social Interaction Anxiety in Adults With Social Anxiety Disorder
Lead sponsor
Gedeon Richter Plc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 12, 2026
Completion date
February 13, 2028
Enrollment
156 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder

Arms

As registered; 2 arms.

  • Group receiving RGH-202 ExperimentalRGH-202

    Oral capsule dosage form applied once daily for 42 days

  • Group receiving Placebo Placebo comparatorPlacebo

    Oral capsule dosage form applied once daily for 42 days

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Incidence and severity of adverse events From enrollment to the end of follow-up at 8 week

Lead sponsor's other trials

Gedeon Richter Plc., most recent start first.

+7 more trials

Similar trials

Same condition (Phobia, Social) and phase, most recent start first.